The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Sep. 4, 4:57 PM

Slide #19. BG Medicine, Inc. Secondary Offering

Company: BG Medicine, Inc. (NASDAQ:BGMD)
Date announced: 8/12/2015
Shares Offered: 2,500,000
Date of Pricing: 8/13/2015
Price Per Share: $1.00
Secondary Offering Details: BG Medicine, Inc., the developer of the BGM Galectin-3 Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 8/13 - The company is offering 2,315,654 Series A units, each consisting of one share of common stock and one half of a warrant to purchase one share of common stock, at a purchase price of $1.00 per Series A unit. The company is also offering 184,346 Series B units, in lieu of Series A units, at a purchase price of $1.00 per Series B unit to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 9.99% of the company's outstanding common stock following the completion of the offering. Each Series B unit consists of one fully pre-funded warrant to purchase one share of common stock and one half of a warrant to purchase one share of common stock. The warrants (other than the fully pre-funded warrants) will have an exercise price of $1.00 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $2.1 million. There is no established public trading market for the pre-funded warrants or the warrants and the company does not expect a market for these securities to develop. The offering is expected to close on August 18, 2015, subject to customary closing conditions.

BG Medicine is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. Co. has two diagnostic tests, the first of which is the BGM Galectin-3® Test for measuring galectin-3 levels in blood plasma for use as an aid in assessing the prognosis of patients diagnosed with heart failure, available as a blood test in the U.S. and the European Union. The second diagnostic test is the CardioSCORE™ Test, a multi-analyte biomarker-based blood test that is designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and stroke.
Open the BGMD Page at The Online Investor »

Company Name:  BG Medicine Inc
Sector:  Biotechnology

Open the BGMD Page at The Online Investor (in a new window) »

September 4, 2015    4:57 PM Eastern
Quotes delayed 20 minutes

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.